The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation SUNNYVALE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — 23andMe Holding Co. (“23andMe”), a leading consumer genetics and research company, today received FDA clearance for a … Continue reading FDA Clearance for 23andMe genetic test on Hereditary Prostate Cancer Marker